India in discussions with Pfizer to obtain 50M doses of COVID-19 vaccine

  • India is in talks with Pfizer (NYSE:PFE) to procure 50M doses of its coronavirus vaccine, as per a New York Times report.
  • Pfizer was prepared to supply India with 50M vaccine doses from July to October and has shared details regarding the drug efficacy to health authorities.
  • However, the government is still considering the company's demand for indemnity from costs related to severe side effects, officials have said.
  • India has not given indemnity, or protection from legal liability, to any manufacturer, but is likely to grant Pfizer 's request.
  • 'We are examining this request, and we will take decisions in the larger interest of people and on merits," says Vinod Paul, head of Indian government's vaccination program.
  • Pfizer has obtained indemnity in several countries where its vaccine is already in use, including the U.S.

    Tomorrow the American Pfizer will publish its past quarter figures. For this year Pfizer 's (located in New York City) revenue will be around 73.07 billion USD. This is according to the average of the analysts' estimates. This is hugely more than 2020's revenue of 41.91 billion USD.

    Historical revenues and results Pfizer plus estimates 2020

    aandeel

    The analysts expect for 2021 a net profit of 21.48 billion USD. For this year the consensus of the result per share is a profit of 3.75 USD. The price-earnings-ratio equals 10.44.

    Huge dividend Pfizer

    Per share the analysts expect a dividend of 1.57 USD per share. Pfizer 's dividend yield thus equals 4.01 percent. The average dividend yield of the pharmaceutical companies is a low 1.39 percent.

    Newest target prices around 42 USD

    The most recent recommendations for the pharmaceutical company are from Goldman Sachs , JP Morgan and Barclays .

    Pfizer 's market capitalization is based on the number of outstanding shares around 216.66 billion USD. The Pfizer stock was the past 12 months quite volatile. Since last June the stock is 20 percent higher. This year the stock price moved between 30 and 43 dollar.

    Historical stock prices Pfizer

    historical stocks pfizer

    On Friday the stock closed at 39.15 USD.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.

    • Other stock news
    Pfizer CEO Bourla says company prepared if modified COVID vaccine required
    Pfizer now in top highest dividend yields in America
    Pfizer to broaden RSV portfolio with deal to acquire ReViral for up to $525 million
    Analysts expect revenue increase Pfizer, quite high dividend
    DoD awards Pfizer $1.4B contract modification for 200M COVID vaccine doses for donation
    Pfizer awarded $3.5 billion contract by U.S. Army to produce COVID-19 vaccines
    Pfizer to begin clinical trials for a COVID-19 shot targeting Delta variant
    Sector news
    Analysts anticipate for 2024 on revenue increase Astrazeneca, high dividend yield
    High dividend yield Sanofi-Aventis
    Sanofi-Aventis in top French dividend returns
    Novartis among highest Swiss dividend stocks
    Analysts expect over 2023 revenue increase UCB
    Pfizer CEO Bourla says company prepared if modified COVID vaccine required
    Analysts: this year best year ever for Carl Zeiss Meditec
    National news
    NXP reaps benefits from FRAMOS collaboration
    Tesla net onder de 500.000 cars per year
    Analysts expect over 2024 revenue decrease Caterpillar
    Analysts expect sales decline Biogen
    Analysts anticipate for 2024 on revenue increase Cognizant
    Analysts expect over 2024 growing sales Colgate-Palmolive
    Analysts expect over 2024 revenue expansion Patterson-UTI Energy, relatively high dividend
    Press news
    Test News
    Unveiling TechEdge Dynamics, The Growth Studio for Consistent Business Success
    ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Applied Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLT
    ROSEN, TRUSTED INVESTOR COUNSEL, Encourages $JENNER Purchasers to Secure Counsel Before Important Deadline in Securities Class Action
    ROSEN, LEADING TRIAL ATTORNEYS, Encourages Customers Bancorp, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – CUBI
    Discover the JOC (Japan Open Chain) Listing on XT
    ASPI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ASP Isotopes Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
    Logoanalist
    Returns European stocks
    Crypto currencies information
    About us Network Partners
    Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos Analist.nlLinksISIN
  • Glossary
    		• MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-xBats
    ©2024 ValueSpectrum. All Rights Reserved
    Developed and maintained by  Velainn logo